A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors

BACKGROUND: Escalating healthcare costs are necessitating the practice of value-based oncology. It is crucial to critically evaluate the economic impact of influential but expensive therapies such as immune checkpoint inhibitors (ICIs). To date, no systematic assessment of the cost-effectiveness (CE...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Vivek, Sprave, Tanja, Haque, Waqar, Simone, Charles B., Chang, Joe Y., Welsh, James W., Thomas, Charles R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251215/
https://www.ncbi.nlm.nih.gov/pubmed/30470252
http://dx.doi.org/10.1186/s40425-018-0442-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251215/
https://www.ncbi.nlm.nih.gov/pubmed/30470252
http://dx.doi.org/10.1186/s40425-018-0442-7

Ejemplares similares